Effect of DLBS1033 on Functional Outcomes for Patients with Acute Ischemic Stroke: A Randomized Controlled Trial.

ABSTRACT:

Background

There are still some unmet needs for stroke management and safety. DLBS1033 is a protein fraction extracted from the earthworm Lumbricus rubellus that has shown fibrinolytic and fibrinogenolytic activities, reduces blood viscosity, and inhibits platelet aggregation that it can be considered an add-on therapy and potential medical breakthrough in acute ischemic stroke management.

Objective

This study is aimed at measuring the benefit of DLBS1033 in acute ischemic stroke management.

Methods

This was a randomized, open-label trial at a referral stroke center from November 2019 to December 2020. Subjects who met the inclusion criteria were randomly divided into a control group and an experimental group. The control group received standard therapy consist

SUBMITTER: Pinzon RT 

PROVIDER: S-EPMC8049819 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature